Subgroup analyses found that SGLT-2 inhibitors were more effective than the control groups and DPP-4 inhibitors in lowering AKI events in patients with CVD, CKD, and ACEi/ARB treatment. The gene discussed is SLC5A2; the disease is chronic kidney disease.